GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vir Biotechnology Inc (NAS:VIR) » Definitions » FCF Margin %

Vir Biotechnology (Vir Biotechnology) FCF Margin % : -1,139.99% (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Vir Biotechnology FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Vir Biotechnology's Free Cash Flow for the three months ended in Dec. 2023 was $-109.46 Mil. Vir Biotechnology's Revenue for the three months ended in Dec. 2023 was $9.60 Mil. Therefore, Vir Biotechnology's FCF Margin % for the quarter that ended in Dec. 2023 was -1,139.99%.

As of today, Vir Biotechnology's current FCF Yield % is -77.22%.

The historical rank and industry rank for Vir Biotechnology's FCF Margin % or its related term are showing as below:

VIR' s FCF Margin % Range Over the Past 10 Years
Min: -46391.28   Med: -2026.53   Max: 100.93
Current: -2026.53


During the past 7 years, the highest FCF Margin % of Vir Biotechnology was 100.93%. The lowest was -46391.28%. And the median was -2026.53%.

VIR's FCF Margin % is ranked worse than
82.06% of 1031 companies
in the Biotechnology industry
Industry Median: -148.24 vs VIR: -2026.53


Vir Biotechnology FCF Margin % Historical Data

The historical data trend for Vir Biotechnology's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vir Biotechnology FCF Margin % Chart

Vir Biotechnology Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Margin %
Get a 7-Day Free Trial -19,489.73 -293.69 -6.38 100.93 -2,026.53

Vir Biotechnology Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 103.50 -283.97 3,133.97 3,893.19 -1,139.99

Competitive Comparison of Vir Biotechnology's FCF Margin %

For the Biotechnology subindustry, Vir Biotechnology's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vir Biotechnology's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vir Biotechnology's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Vir Biotechnology's FCF Margin % falls into.



Vir Biotechnology FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Vir Biotechnology's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-800.358/39.494
=-2,026.53 %

Vir Biotechnology's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-109.462/9.602
=-1,139.99 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vir Biotechnology FCF Margin % Related Terms

Thank you for viewing the detailed overview of Vir Biotechnology's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Vir Biotechnology (Vir Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
499 Illinois Street, Suite 500, San Francisco, CA, USA, 94158
Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
Executives
Svf Endurance (cayman) Ltd 10 percent owner C/O WALKERS CORPORATE LIMITED, 27 HOSPITAL ROAD, GEORGE TOWN E9 KY1-9008
Vicki L Sato director 940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451
Phillip Pang officer: Chief Medical Officer C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Steven J. Rice officer: Chief Administrative Officer C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Saira Ramasastry director 501 CANAL BLVD., RICHMOND CA 94804
Backer Marianne De officer: Chief Executive Officer 177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Ann M. Hanly officer: Chief Technology Officer C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Sung Lee officer: Chief Financial Officer 7000 MARINA BLVD, BRISBANE CA 94005
Johanna Friedl-naderer officer: Chief Business Officer, Global C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
George A Scangos director, officer: President and CEO C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083
Howard Horn officer: CFO C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Charles Elliott Sigal director 32 BREARLY ROAD, PRINCETON NJ 08540
Herbert Virgin officer: EVP, Research & CSO C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Janet Napolitano director C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Robert J More director 680 S CACHE STREET, SUITE 100, BOX 10820, JACKSON WY 83001

Vir Biotechnology (Vir Biotechnology) Headlines

From GuruFocus